Skip to main content
Premium Trial:

Request an Annual Quote

Inching Toward Acquisition by ViroLogic, Aclara Posts 34-Percent Decline in Q3 Revenue

NEW YORK, Nov. 9 (GenomeWeb News) - Aclara today reported a 34-percent decline in third-quarter revenue as costs for its impending acquisition by ViroLogic helped widen net losses.

 

Total receipts for the three months ended Sept. 30 fell to $181,000 from $276,000 year over year.

 

The company, which is slated to be acquired by VioroLogic during the fourth quarter, said net losses for the period fell to $4 million, or $.11 per share, from $4.9 million, or $.14 per share, year over year.

 

As GenomeWeb News reported in June, Aclara said it would be acquired by ViroLogic for around $180 million in order to develop and commercialize Aclara's eTag assays for molecular diagnostic applications. The new company will be called ViroLogic.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.